The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

After a recent video, someone from the National Geographic Society reached out to give me an updated set of their atlases. Today I open them up to see if there's anything new worth seeing.

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use ...

I know we wanna cheat the system as Americans, we do,” the 53-year-old tells Page Six in an exclusive interview.